You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

  1. PAR-21-224: NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)

    Release Date: 05-05-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose: To facilitate the cooperation and partnering of public and private funding organizations, universities, academic medical centers, research institutes, contract research organizations, biotechnology companies, and pharmaceutical companies, NINDS has formed the Neurology Network of Excellence in Clinical Trials (NeuroNEXT, www.NeuroNEXT.org). NeuroNEXT has a Clinical Coordinating Center (C ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. NIH/NCI 436: New Technologies to Analyze Extra-Chromosomal DNA in Cancer

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 2-3 Budget (total costs, per award): Phase I: up to $400,000 for up to 12 months Phase II: up to $2,000,000 for up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Summary Numerous studies over the last several decades have reported ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. PAR-21-082: NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)

    Release Date: 01-14-2021Open Date: 04-14-2021 Due Dates: Multiple Close Date: 01-15-2024

    Purpose This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. A clinical trial is defined by NIH as: "A research study in which one or more human subjects are prospectivel ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. RFA-AG-22-007: NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional)

    Release Date: 06-10-2021Open Date: 09-26-2021Due Date: 10-26-2021Close Date: 10-27-2021

    The number of available tenure-track faculty positions has not kept pace with the growing number of Ph.D. graduates in recent years. This imbalance has created a very competitive job environment, making it increasingly difficult for Ph.D. graduates to transition to academic appointments. Doctoral and post-doctoral training programs have heavily revolved around developing skill sets that are direct ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. PAR-21-266: NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)

    Release Date: 07-16-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. PAR-21-265: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)

    Release Date: 07-16-2021Open Date: 08-05-2021 Due Dates: Multiple Close Date: 04-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. PAR-21-114: NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed)

    Release Date: 01-25-2021Open Date: 03-05-2021 Due Dates: Multiple Close Date: 01-06-2024

    Purpose NINDS is committed to advancing diagnostics and treatments for people burdened by neurological diseases, and the NINDS Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have provided the small business community with critical seed funding to support the development of a wide variety of technologies and therapeutics for the diagnosis and treat ...

    SBIRPhase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. PAR-20-098: Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed)

    Release Date: 02-06-2020Open Date: 03-05-2020 Due Dates: Multiple Close Date: 01-06-2022

    Research Objectives Maximizing the therapeutic impact of somatic genome editing requires the development of safe and effective technologies to deliver genome editing machinery into all disease-relevant somatic cells and tissues. Therefore, the objective of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with th ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. NIH/NIAID 101: Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines

    Release Date: 07-12-2021Open Date: 07-12-2021Due Date: 10-28-2021Close Date: 10-28-2021

    Fast-Track Proposals will be accepted. Direct-to-Phase II will not be accepted. Number of anticipated awards: 2-4 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $2,000,000 for up to 3 years. Background Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broa ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. RFA-HG-20-016 : Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)

    Release Date: 03-19-2020Open Date: 03-25-2020 Due Dates: Multiple Close Date: 06-24-2022

    Purpose This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in commercial synthetic nucleic acid synthesis and constructs. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained synthetic nucleic acid increased ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government